---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-401010"
form_type: "8-K"
ticker: "COAG"
cik: "0002114044"
company_name: "Hemab Therapeutics Holdings, Inc."
filed_at: "2026-09-24T20:03:23+00:00"
generated_at: "2026-09-24T20:04:30.099807+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Hemab appoints Keli Walbert to board and audit committee effective Sept 24, 2026

## Summary
- Keli Walbert elected Class I director, term expiring at 2027 annual meeting; also joins Audit Committee.
- Granted option to purchase 36,000 shares at closing price on Sept 24, 2026; vests monthly over 3 years.
- Annual cash compensation $40,000 (board) plus $10,000 (Audit Committee); equity grants per policy.
- Vesting accelerates in full on change of control; standard indemnification agreement applies.
- No family relationships or reportable transactions with company; no arrangement behind election.

## SEC filing metadata
- accession: 0001193125-26-401010
- form_type: 8-K
- ticker: COAG
- cik: 0002114044
- company_name: Hemab Therapeutics Holdings, Inc.
- filed_at: 2026-09-24T20:03:23+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/0001193125-26-401010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/d35700d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-401010
- JSON: https://secwatch.observer/filing/0001193125-26-401010.json
- Plain text: https://secwatch.observer/filing/0001193125-26-401010.txt

## Key facts
- Executive change
  Keli Walbert was elected as Director at Hemab Therapeutics Holdings, Inc..
  - Action: elected
  - Role: Director
  source text: On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/0001193125-26-401010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.